Emerging light-powered cancer treatment gets a nanotech upgrade
en-GBde-DEes-ESfr-FR

Emerging light-powered cancer treatment gets a nanotech upgrade

27/03/2026 Frontiers Journals

Photodynamic therapy (PDT) uses light to activate special drugs called photosensitizers to destroy cancer cells with high precision. The basic principle behind PDT is the interaction between light, a photosensitive molecule, and oxygen inside the tumor. When light shines on the photosensitizer, it becomes excited and transfers energy to surrounding oxygen, producing highly reactive species that damage and kill cancer cells. Much like a guided missile that only explodes at its target, PDT works only where both the drug and light meet. Liposomal nanotechnology enhances this process by packaging the photosensitizer inside tiny fat-based carriers that protect the drug in the bloodstream and deliver it directly to tumors. These liposomes improve stability, targeting, and drug concentration at the disease site. In fact, liposome-assisted PDT has become one of the most promising strategies in modern cancer nanomedicine, offering improved selectivity, reduced side effects, and better therapeutic outcomes.
This work demonstrates how modern nanotechnology can significantly enhance photodynamic therapy by using liposomes to protect drugs in the bloodstream, deliver them precisely to tumours, and release them exactly where light is applied, increasing treatment effectiveness while reducing side effects— a major step toward more personalised and targeted cancer care. This advancement matters to the public because cancer affects millions worldwide, and safer, more precise treatments offer fewer side effects, improved quality of life, and greater hope for patients. Led by Prof. Heidi Abrahamse at the Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, our multidisciplinary team, with expertise in nanotechnology, photomedicine, and cancer biology, has developed a platform that integrates physics, chemistry, and medicine to revolutionise the delivery of light-based cancer therapies.
The work entitled “Recent trends in liposomal drug efficiency of nanotechnology in photodynamic therapy for cancer” was published in Frontiers of Optoelectronics (published on Feb. 2, 2026).
DOI:10.2738/foe.2026.0005
Archivos adjuntos
  • Image: Recent trends in liposomal drug efficiency of nanotechnology in photodynamic therapy for cancer
27/03/2026 Frontiers Journals
Regions: Asia, China
Keywords: Applied science, Nanotechnology, Health, Medical

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Testimonios

We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

Trabajamos en estrecha colaboración con...


  • e
  • The Research Council of Norway
  • SciDevNet
  • Swiss National Science Foundation
  • iesResearch
Copyright 2026 by DNN Corp Terms Of Use Privacy Statement